HOME >> MEDICINE >> NEWS
Three Harvard Medical School endowed chairs named simultaneously in sleep medicine

Boston, MA - May 11, 2004 - Harvard Medical School (HMS) is taking steps to dramatically advance the field of Sleep Medicine through the simultaneous establishment of three endowed chairs all devoted to this emerging critical field of medicine.

Joseph B. Martin, Dean of HMS, hailed today's announcement as an historic moment for the school and in the evolution of the field of Sleep Medicine. "This generous and timely support will greatly accelerate advances in sleep and circadian rhythm research. At a time when nearly 40 million Americans suffer with sleep disorders, many find numerous barriers to diagnosis and treatment," said Martin, MD, PhD. "These gifts will enable HMS to take a leading role in this interdisciplinary field, ensuring the advancement of scientific research and the development of new treatments for sleep disorders."

The three chairs are named after the founders and Chairmen of three publicly listed companies that have been innovators in sleep therapy: Dr. Frank Baldino, CEO of Cephalon, Inc., Mr. Gerald E. McGinnis, Board Chairman, of Respironics, and Dr. Peter C. Farrell, CEO of ResMed. Each chair was funded by unrestricted gifts from their companies or themselves.

Recognizing the importance of this scientific discipline, Martin established the Division of Sleep Medicine at HMS in 1997. "The goal of the HMS Division of Sleep Medicine has been to establish sleep disorders medicine as a formally recognized medical discipline, and to forge a path of discovery while providing training for the next generation of national leaders in this discipline," said Martin.

President of Brigham and Women's Hospital, Gary Gottlieb, MD, MBA, concurs, "These three chairs will positively impact research and clinical treatments for dangerous and disabling sleep disorders," he said. "The professorships are being created in honor of visionary leaders in the health care industry."

Martin said that the three men whose names will be on
'"/>

Contact: Judith Montminy
public_affairs@hms.harvard.edu
617-432-0442
Harvard Medical School
11-May-2004


Page: 1 2 3 4 5

Related medicine news :

1. Three-year cervical cancer screening recommendations may be applicable for certain women with HIV
2. Three anti-platelet drugs used in combination are safe
3. Three out of the four million newborn babies who die each year could be saved
4. Three-year health study of teenage girls is underway at Trenton Central High School
5. Three months is too soon to judge a CML patients response to Gleevec, researchers find
6. Three Abbott chemists honored as Heroes for development of HIV therapy for children
7. Three Pfizer Inc chemists win Heroes award for epilepsy treatment for children, adults
8. Three Merck chemists win Heroes of Chemistry award for major asthma treatment advance
9. Three-time Emmy Award winning actress Kathy Baker to participate in ADHD experts on call program
10. Three-month antibiotic treatment reduces risk of future heart attack
11. Irritable Bowel Syndrome The Focus Of Three UNC-CH Reports At Digestive Diseases Conference

Post Your Comments:
(Date:10/25/2014)... NC (PRWEB) October 25, 2014 Mesothelioma ... who continued to receive pemetrexed (Alimta), after his combination ... read the full story , just posted on the ... from Uji Tokushukai Medical Center in Japan suggests that ... mesothelioma patients who cannot tolerate higher doses ...
(Date:10/25/2014)... Interrupting blood supply to an arm or a leg before ... surgery, according to a new study. "During heart ... heart to be able to operate on it. After some ... to produce energy because it doesn,t get oxygen. When we ... as an arm or a leg, the body prepares for ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Not getting the ... ulcerative colitis, a new study suggests. Those who ... eight hours per night may be more prone to ... intestines, researchers report. The study authors concluded that duration ... considered among patients with inflammatory bowel diseases. "Both ...
(Date:10/25/2014)... A large influx of international aid is needed, and ... thousands of deaths from the widening Ebola crisis, a ... a specially designed mathematical model, the researchers looked at ... densely populated county of hard-hit Liberia -- Montserrado County, ... researchers said that if international aid isn,t delivered to ...
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... tests are developed that spot increased risks for certain cancers, ... about getting screened. But a new study suggests that, ... People who found out their genes doubled their risk of ... risk to get screened. "It didn,t make any difference, ...
Breaking Medicine News(10 mins):Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Brief Interruption of Blood Supply to Limb Might Aid Heart Surgery: Study 2Health News:Sleep Duration Linked to Ulcerative Colitis Risk in Study 2Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
(Date:10/25/2014)... , Oct. 24, 2014 Burzynski Research ... and Drug Administration (FDA) has given the company permission ... AS2-1 in patients > 3 months of age with ... be placed in one of five treatment groups based ... received prior treatment for DIPG. The primary study endpoint ...
(Date:10/22/2014)... 22, 2014  Cephasonics, a technology-innovation leader with a ... cQUB™-1 (cQuest Ultrasound Box™-1), the first product in a ... manufactured by Cephasonics for purchase by companies to rebrand ... will be showcasing the cQUB-1 for the first time ... Chongqing, China from October 23 ...
(Date:10/22/2014)... 22, 2014 Antigen Discovery Inc. (ADi), a ... , announced the receipt of a National Institutes of ... from the National Institute of Dental and Craniofacial Research (NIDCR). ... a Pan-HIV Protein Microarray Chip, which will contain every ... and aid in the development of safe and effective ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
Cached News: